Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Distribution equality as an optimal epidemic mitigation strategy

Adar Hacohen, Reuven Cohen, Sol Efroni, View ORCID ProfileIdo Bachelet, Baruch Barzel
doi: https://doi.org/10.1101/2020.09.15.20194506
Adar Hacohen
1Augmanity, Rehovot, Israel
2Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reuven Cohen
3Department of Mathematics, Bar-Ilan University, Ramat-Gan, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sol Efroni
2Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ido Bachelet
1Augmanity, Rehovot, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ido Bachelet
Baruch Barzel
3Department of Mathematics, Bar-Ilan University, Ramat-Gan, Israel
4The Gonda Multidisciplinary Brain Research Center, Bar-Ilan University, Ramat-Gan, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: baruchbarzel@gmail.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Upon the development of a drug or vaccine, a successful response to a global pandemic, such as COVID-19, requires the capacity for efficient distribution at a global scale. Considering constraints on production and shipping, most existing strategies seek to maximize the outflow of therapeutics, hence optimizing for rapid dissemination. Surprisingly, we find that this intuitive approach is counterproductive. The reason is that focusing strictly on the quantity of disseminated therapeutics, such strategies disregard their specific spreading patterns, most crucially – they overlook the interplay of these spreading patterns with those of the pathogens. This results in a discrepancy between supply and demand, that prohibits efficient mitigation even under optimal conditions of superfluous drug/vaccine flow. Therefore, here, we design a dissemination strategy that naturally follows the predicted spreading patterns of the epidemic, optimizing not just for supply volume, but also for its congruency with the anticipated demand. Specifically, we show that epidemics spread relatively uniformly across all destinations, and hence we introduce an equality constraint into our dissemination that prioritizes supply homogeneity. This strategy may, at times, slow down the supply rate in certain locations, however, thanks to its egalitarian nature, which mimics the flow of the viral spread, it provides a dramatic leap in overall mitigation efficiency, saving more lives with orders of magnitude less resources.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This research was supported by the Israel Science Foundation grant no. 499/19 and by the Israel Council for Higher Education (VATAT) Grant for data science research.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Not applicable

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Upon publication, the authors plan to make all datasets and numerical codes publicly available.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted September 18, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Distribution equality as an optimal epidemic mitigation strategy
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Distribution equality as an optimal epidemic mitigation strategy
Adar Hacohen, Reuven Cohen, Sol Efroni, Ido Bachelet, Baruch Barzel
medRxiv 2020.09.15.20194506; doi: https://doi.org/10.1101/2020.09.15.20194506
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Distribution equality as an optimal epidemic mitigation strategy
Adar Hacohen, Reuven Cohen, Sol Efroni, Ido Bachelet, Baruch Barzel
medRxiv 2020.09.15.20194506; doi: https://doi.org/10.1101/2020.09.15.20194506

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (49)
  • Cardiovascular Medicine (448)
  • Dentistry and Oral Medicine (80)
  • Dermatology (55)
  • Emergency Medicine (157)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (190)
  • Epidemiology (5218)
  • Forensic Medicine (3)
  • Gastroenterology (194)
  • Genetic and Genomic Medicine (750)
  • Geriatric Medicine (77)
  • Health Economics (212)
  • Health Informatics (694)
  • Health Policy (352)
  • Health Systems and Quality Improvement (223)
  • Hematology (98)
  • HIV/AIDS (162)
  • Infectious Diseases (except HIV/AIDS) (5820)
  • Intensive Care and Critical Care Medicine (356)
  • Medical Education (102)
  • Medical Ethics (25)
  • Nephrology (80)
  • Neurology (758)
  • Nursing (43)
  • Nutrition (129)
  • Obstetrics and Gynecology (141)
  • Occupational and Environmental Health (231)
  • Oncology (475)
  • Ophthalmology (149)
  • Orthopedics (38)
  • Otolaryngology (94)
  • Pain Medicine (39)
  • Palliative Medicine (19)
  • Pathology (139)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (96)
  • Psychiatry and Clinical Psychology (854)
  • Public and Global Health (1994)
  • Radiology and Imaging (344)
  • Rehabilitation Medicine and Physical Therapy (157)
  • Respiratory Medicine (283)
  • Rheumatology (93)
  • Sexual and Reproductive Health (72)
  • Sports Medicine (75)
  • Surgery (108)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)